Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

101 to 125 of 417 results

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

19-12-2013

The US Food and Drug Administration late yesterday approved Anoro Ellipta (umeclidinium and vilanterol…

Anoro ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

18-12-2013

US pharma giant Merck & Co says it has initiated a clinical trial to evaluate the combination of the…

GlaxoSmithKlineMerck & CoMK-3475OncologyPazopanib TabletsPharmaceuticalResearch

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

17-12-2013

In the wake of the bribery scandal in China, as well as a record-breaking $3 billion fine in the USA…

GlaxoSmithKlineGlobalManagementMarkets & MarketingPharmaceutical

GlaxoSmithKline to lift stake in Indian subsidiary to 75%

GlaxoSmithKline to lift stake in Indian subsidiary to 75%

16-12-2013

UK pharma major GlaxoSmithKline said this morning that it plans to increase its stake in its publicly-listed…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding

13-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

GSK’s Synflorix gets additional indication in Europe

GSK’s Synflorix gets additional indication in Europe

05-12-2013

The European Commission has granted marketing authorization for an additional indication for UK pharma…

Antibiotics and Infectious diseasesEuropeGlaxoSmithKlinePharmaceuticalRegulationSynflorix

CHMP positive opinion for GSK’s Cervarix two-dose schedule

CHMP positive opinion for GSK’s Cervarix two-dose schedule

28-11-2013

UK pharma giant GlaxoSmithKline says that the European Medicines Agency's Committee for Medicinal Products…

CervarixEuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVaccines

US patient share leaders in first-line BRAF-mutation positive malignant melanoma

27-11-2013

According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

US FDA clears GlaxoSmithKline’s H5N1 flu vaccine

26-11-2013

The US Food and Drug Administration has approved UK pharma giant GlaxoSmithKline’s pandemic Influenza…

GlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

US FDA eases restrictions on GSK diabetes drug Avandia

US FDA eases restrictions on GSK diabetes drug Avandia

26-11-2013

The US Food and Drug Administration yesterday (November 25) lifted some severe limitations on the prescribing…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

GlaxoSmithKline invests further £25 million in Scottish operation

GlaxoSmithKline invests further £25 million in Scottish operation

23-11-2013

UK pharma giant GlaxoSmithKline is to invest £25 million ($40.2 million) to expand its operations in…

EuropeFinancialGlaxoSmithKlinePharmaceuticalProduction

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy

22-11-2013

Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…

GlaxoSmithKlineMekinistOncologypalbociclibPfizerPharmaceuticalResearchtrametinib

GlaxoSmithKline cashes in $694 million of Aspen shares

GlaxoSmithKline cashes in $694 million of Aspen shares

21-11-2013

UK pharma giant GlaxoSmithKline said yesterday that it has agreed to the sale of 28.2 million ordinary…

Aspen PharmacareFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

Relvar Ellipta approved for asthma and COPD in Europe

Relvar Ellipta approved for asthma and COPD in Europe

19-11-2013

The European Commission has granted marketing authorization for Relvar Ellipta (fluticasone furoate/vilanterol…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

12-11-2013

UK pharma giant GlaxoSmithKline saw its shares dip 1.3% to £16.29 in mid-morning trading, after the…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK

07-11-2013

UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…

EuropeFinancialGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearchUK

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

101 to 125 of 417 results

Back to top